Cuban TV host says Fidel Castro admired Russian peopleWorld December 04, 5:17
Voting gets underway in Uzbekistan to elect new presidentWorld December 04, 4:41
Mass rally in memory of Fidel Castro begins in Santiago de CubaWorld December 04, 3:32
Patriarch Kirill urges compatriots to cherish spiritual ties with homelandSociety & Culture December 04, 2:40
Fidel Castro’s funeral to be held in Santiago de CubaWorld December 04, 1:50
38 ceasefire violations by militants reported in Syria in 24 hoursRussian Politics & Diplomacy December 04, 1:23
Boxer Gassiev beats Lebedev to become IBF cruiserweight world champSport December 04, 0:47
Uzbekistan to hold presidential electionWorld December 04, 0:45
Ukraine does not need position of president - TimoshenkoWorld December 03, 23:52
NOVOSIBIRSK, June 9. /TASS/. A new vaccine to protect against Ebola virus disease developed by Russia’s Vector research center of virology and biotechnology has successfully undergone the first stage of clinical tests, the acting director general of the research center told reporters on the sidelines of the international forum for technological development on Thursday.
"The first phase of clinical tests has been completed. It is now on approval at the Russian Ministry of Healthcare. We are waiting for a second phase," Valery Mikheyev said.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected. In January, Russia informed the WHO executive committee about its anti-Ebola vaccines.
The World Health Organization describes Ebola virus disease (formerly known as Ebola haemorrhagic fever) as "a severe, often fatal illness, with a case fatality rate of up to 90%." Until now, there has been no known cure or vaccine for the disease. The only treatment offered is "supportive intensive care." During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients.